Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults
First and Only Two-Dose Vaccine in United States for Prevention of Hepatitis B in AdultsFirst New Hepatitis B Vaccine in United States in More than 25 YearsCompany to Host Conference Call/Webcast Today at 5:00 p.m. ET
View HTML
Toggle Summary Dynavax Reports Third Quarter 2017 Financial Results
BERKELEY, CA -- (Marketwired) -- 11/03/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2017 . Cash, cash equivalents and marketable securities were $191.7 million at September 30, 2017 compared to $81.4 million at
View HTML
Toggle Summary Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy
Dynavax Expands its TLR9 Agonist Platform in Combination with Anti-PD-1 Therapy to a Third Tumor Type
View HTML
Toggle Summary Dynavax to Present at Upcoming Investor Conferences
BERKELEY, CA -- (Marketwired) -- 09/05/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the company will present at two upcoming investor conferences in September. NewsMakers in the Biotech Industry Investor Conference Friday, September 8, 2017 in New York at 8:30 a.m.
View HTML
Toggle Summary Dynavax Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
BERKELEY, CA -- (Marketwired) -- 08/15/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of an underwritten public offering of 5,750,000 shares of its common stock, including 750,000 shares sold pursuant to the full exercise of an over-allotment option previously
View HTML
Toggle Summary Dynavax Prices Public Offering of Common Stock
BERKELEY, CA -- (Marketwired) -- 08/09/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of a previously announced underwritten public offering of 5,000,000 shares of its common stock, offered at a price to the public of $15.00 per share.
View HTML
Toggle Summary Dynavax Announces Proposed Public Offering of Common Stock
BERKELEY, CA -- (Marketwired) -- 08/08/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell $125.0 million of shares of its common stock, subject to market and other conditions, in an underwritten public offering.
View HTML
Toggle Summary Dynavax Provides U.S. Regulatory Update on HEPLISAV-B(TM) Following FDA Advisory Committee Meeting
Conference call today at 4:30 p.m. EDT
View HTML
Toggle Summary Dynavax Reports Second Quarter 2017 Financial Results
BERKELEY, CA -- (Marketwired) -- 08/02/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2017 . Cash, cash equivalents and marketable securities were $127.0 million at June 30, 2017 compared to $81.4 million at December 31,
View HTML
Toggle Summary Dynavax Announces FDA Advisory Committee Vote in Favor of HEPLISAV-B(TM)
BERKELEY, CA -- (Marketwired) -- 07/28/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 12 to 1 that the safety data for HEPLISAV-B [Hepatitis B
View HTML